Lack of efficacy of mefloquine in the treatment of new world cutaneous leishmaniasis in Colombia
ABSTRACT: In a nonblinded, therapeutic trial conducted in Colombia, 1.25–1.5 grams of mefloquine base given as a single oral dose or as 250 mg a day for 5–6 consecutive days was not efficacious in the treatment of New World cutaneous leishmaniasis. The drug had cured only 30.8% of patients with leis...
| Autores: | , , , |
|---|---|
| Formato: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 1998 |
| País: | Colombia |
| Recursos: | Universidad de Antioquia |
| Repositorio: | Repositorio UdeA |
| Idioma: | inglés |
| OAI Identifier: | oai:bibliotecadigital.udea.edu.co:10495/32064 |
| Acesso em linha: | https://hdl.handle.net/10495/32064 |
| Access Level: | acceso abierto |
| Palavra-chave: | Antimaláricos Antimalarials Leishmaniasis Cutánea Leishmaniasis, Cutaneous Mefloquina Mefloquine |
| Resumo: | ABSTRACT: In a nonblinded, therapeutic trial conducted in Colombia, 1.25–1.5 grams of mefloquine base given as a single oral dose or as 250 mg a day for 5–6 consecutive days was not efficacious in the treatment of New World cutaneous leishmaniasis. The drug had cured only 30.8% of patients with leishmaniasis skin lesions by the 10th week after start of therapy as compared with a 27.9% complete cicatrization rate in historical controls treated with placebo tablets and an 86.3% cicatrization rate in historical controls who received meglumine antimoniate, 20 mg/ kg/day intramuscularly for 20 days, with no upper limit to daily dose. It is concluded that a single course treatment with mefloquine is not indicated as monotherapy in the treatment of Colombian cutaneous leishmaniasis primarily due to L. panamensis. |
|---|